Washington, D.C., June 19, 2025, The U.S. food and Drug administration (FDA) has authorised a groundbreaking HIV prevention injection developed by way of Gilead Sciences, marking a main milestone in the fight in opposition to the virus.

The drug, lenacapavir, will be advertised beneath the logo name Yeztugo and is run just two times a 12 months. It offers a protracted-acting opportunity to traditional pre-exposure prophylaxis (PrEP), which normally calls for daily oral medication.

“This is a historical day in the decades-long combat in opposition to HIV,” stated Daniel O’Day, Gilead’s chairman and CEO. “We’ve an effective new device that could notably lessen new infections and reshape prevention efforts worldwide.

”Scientific trial effects highlight the drug’s super efficacy. In two huge research:One trial, performed with over 2,000 girls in sub-Saharan Africa, confirmed a 100% prevention charge, with no new HIV infections said, outperforming the current well known, Truvada.Another study, related to extra than 2,000 guys and gender-diverse people, reported just two infections, reflecting a 99.9% efficacy price.

Those effects were published within the New England journal of drugs, and the journal technological know-how identified lenacapavir as its 2024 step forward of the year.

Professionals say the ease of biannual dosing ought to dramatically enhance adherence and amplify get right of entry to, in particular in underserved populations.With the FDA’s green light, lenacapavir is now poised to come to be a transformative addition to worldwide HIV prevention strategies.

Sources https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/us-approves-gileads-twice-yearly-injection-to-prevent-hiv/amp_articleshow/121966624.cms

https://news.google.com/read/CBMi6wFBVV95cUxNbGVGNjhIYU5hdktfdFVVd1BoWHhCem1QTDlDQVdMVUc4TTFCNjJzZ3dEWm1iMnhtb2tUSkJ2amVGeVBERTItWmpwNEp4S3d6Y0htbGFtQjNNNmVMbGg5WGdraDB3NlNYUEtRdFBDeXZTaTRJeTQxMjdEalByMVFrd2R4QjZRekhvaGpvYjRhaWpRRDgtSFlRRVItT2pIZzkxR050azdKUFVLaUlmNVAwQTFLLWg5eWRqYU5VVUI1LTllRWpTXzVTaFQ5QkJjMGh5UUhXc214NkFyRGJpdTdKZWFYY2VtQ1Rhalpr0gHwAUFVX3lxTE9yb3FLZWJkWmhhRWVQQ1pCTkREUkxRMlhlY21fbXFxSXUxTXZkcE1Cb2oxZHU3SWNwc3RTWEZFdGZqQTc1emVwWTJZM1BTWE5FZGdQNTVaMEF1dVRDSkVhYnlTY0FtS0lLZVBRRmdBMDcxT1FCcUU2Xy12b3BBSEFDTkU2QVNQN3l2c3NMNThVdVFueXZCS3hzNGFmUUdDZldTR1FRQlNtV0xCdGlEWkFjcEpBT3d5VnR0Z0RNVjltX3FBb1BjSkI0dERsTzNBTF9zX0FCSmxkQUktS1ZvWkNPT0U4WHZHMHIzaDV0SVJBZA?hl=en-IN&gl=IN&ceid=IN%3Aen